After a tumultuous couple of years, large pharma and investors alike are poised and ready to return to the heights of the biotech capital markets. How can microbiome biotechs make sure that their data captures the eye of investors? What gets pharma excited about working with a particular biotech, and are there specific traits that could convince pharma to dip their toes back into the world of microbial innovation?
Speaker(s):
Speakers
Elran Haber, PhD
Chief Executive Officer
Biomica